Health Care • Biotechnology: Pharmaceutical Preparations
$174.00 ▼ -58.40
(-25.13%)
MKT CAP: $23.28B • VOL: 11.80M
52W L $163 52W H $480
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$146
MEDIAN
$195
MEAN
$198
HIGH
$237
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ALNY TAPE
ALNY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $210.54 | $200.10 | 2025-02-14 | $158.34 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $219.24 | $205.32 | 2025-02-06 | $163.56 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $198.36 | $191.40 | 2025-01-29 | $167.04 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $177.48 | — | 2025-01-17 | $170.52 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $153.12 | $165.30 | 2025-01-09 | $154.86 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $207.06 | $180.96 | 2024-12-18 | $151.38 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $168.78 | $175.74 | 2024-12-04 | $161.82 | -4.3% | 48% | C |